Actively Recruiting

Phase 2
Age: 65Years +
All Genders
ID07072195

A Multicenter, Randomized, Double-Blind, Placebo-controlled Phase 2 Trial to Evaluate AMC6156 for Sarcopenia in Older Adults

Led by Animuscure Inc. · Updated on 2025-07-29

80

Participants Needed

4

Research Sites

13 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of AMC6156 on physical function and safety in older adults diagnosed with sarcopenia, a condition characterized by reduced muscle mass and strength. This phase 2 clinical trial aims to determine if AMC6156 can improve movement and muscle strength in this population. The study is randomized, double-blind, and placebo-controlled, ensuring reliable comparison between treatment groups. Participants will be randomly assigned to one of four groups: receiving AMC6156 at doses of 0.1 mg, 0.3 mg, or 1.0 mg once daily, or a matching placebo, all taken orally for 12 weeks. The study includes regular visits at screening, baseline, and weeks 4, 8, and 12 to monitor progress and safety throughout the treatment period. During the study, participants will undergo tests to measure physical performance using the Short Physical Performance Battery (SPPB), Timed Up and Go (TUG) test, handgrip strength, and muscle mass via DXA scans. Quality of life and sarcopenia-specific assessments will also be completed. Safety evaluations and monitoring will occur at regular intervals, with total participation lasting approximately 12 weeks.

CONDITIONS

Brief Title

A Study of AMC6156 in People With Sarcopenia

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntary participation with written informed consent
  • Male aged 65 years or older, or postmenopausal female
  • Diagnosed with sarcopenia with appendicular skeletal muscle mass less than 7.0 kg/m² for men or less than 5.4 kg/m² for women
  • Low handgrip strength or Short Physical Performance Battery (SPPB) score of 9 or less
  • Mini Nutritional Assessment (MNA) screening score of 8 or higher
  • Body weight of at least 35 kg and body mass index (BMI) between 15 and 30 kg/m²
  • Willing and able to follow exercise and nutrition guidance
Not Eligible

You will not qualify if you...

  • Allergy to the investigational drug
  • History of gastrointestinal bleeding, ulcers, or severe liver, kidney, or heart disease
  • QTc interval of 450 ms or more with symptoms
  • Severe chronic obstructive pulmonary disease (COPD), uncontrolled diabetes, or thyroid disease
  • Diseases causing cachexia or muscle wasting such as amyotrophic lateral sclerosis (ALS) or Parkinson's disease
  • Vitamin D deficiency below 10 ng/mL or hemoglobin less than 10 g/dL
  • Severe psychiatric disorders or Mini-Mental State Examination (MMSE) score below 21
  • Inability to walk or recent fracture or surgery affecting mobility
  • Use of prohibited medications or recent participation in other clinical trials
  • Investigator's judgment deeming the subject unsuitable for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 weeks

Participants receive oral AMC6156 or placebo tablets once daily for 12 weeks.

5 visits (Baseline at Week 0, Week 4, Week 8, Week 12, plus Screening visit not included here)

Trial Site Locations

Total: 4 locations

1

CHA Bundang Medical Center

Seongnam-si, Gyeonggi-do, South Korea, 13496

Actively Recruiting

2

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea, 13620

Not Yet Recruiting

3

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea, 16499

Actively Recruiting

4

Seoul National University Hospital

Seoul, Seoul, South Korea, 03080

Actively Recruiting

Loading map...

Research Team

J

Jooyeon Kim

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

A Prospective, Randomized, Double-blinded, Placebo-controlle...

Sarcopenia in Elderly

Actively Recruiting

5 locations

Study of Silkworm Pupa Powder to Improve Nutritional Status ...

AD - Alzheimer's Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here